Received Jun 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | 1 | — | — |
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | 2 | — | — |
No additional AE/PQC; Patient was given their first dose of CAPVAXIVE in February 2025 and a second dose of CAPVAXIVE on 04JUN2025; This spontaneous report was received from an office manager who placed a physician on the line, and refers to a 75-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in February 2025, the adult patient was administered the first dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (dose, route of administration, vaccination site, lot # and expiration date were not reported) for prophylaxis. On 04-Jun-2025, the adult patient was administered the second dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (dose, route of administration, vaccination site, lot # and expiration date were not reported) for prophylaxis (extra dose administered). No additional adverse event (AE) and no product quality complaint (PQC) was noted (no adverse event). No additional information was reported. Lot # is being requested and will be submitted if received.